DBV Technologies S.A. Stock Prediction
AI-powered sentiment analysis and prediction trends for DBVT, updated each market day.
DBVT AI Sentiment
AI sees no strong directional signal for DBV Technologies S.A. stock over the next 10 market days.
Prediction date: May 8, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Sector
Exchange
Market Cap
$1,183,065,691
Cap Tier
Employees
161
Headquarters
CHATILLON, I0
Listed Since
Oct. 22, 2014
Website
DBVT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
DBVT Volatility
DBV Technologies S.A. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
